TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00995150
Drug: LNG20
Normalized name: Levonorgestrel 20 mcg
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: levonorgestrel-releasing intrauterine system for contraception
Study: NCT00995150
Drug: Mirena
Normalized name: Mirena
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mirena intrauterine system
Study: NCT01463046
Drug: Panobinostat
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Induction - 20-60 mg (1-3 20 mg capsules) PO on days 1,3,5 and 8~Second induction - 20-60 mg (1-3 20 mg capsules) PO days 1,3 and 5~Consolidation - 20-60 mg (1-3 20 mg capsules) PO on days 1,3,5 and 8
Study: NCT01463046
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction - 100 mg/m2 continuous IV daily for 7 doses on day 3-9.~Second induction - 100 mg/m2 continuous IV daily for 7 doses on day 3-7.~Dosing for consolidation - 100 mg/m2 continuous IV daily for 7 doses on day 3-9.
Study: NCT01463046
Drug: Daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction - 60 mg/m2 IV over 15-30 minutes daily for 3 doses on day 3-5.~Second induction - 60 mg/m2 IV over 15-30 minutes daily for 2 doses on day 3 and 4.~Dosing for consolidation - 60 mg/m2 IV over 15-30 minutes daily for 3 doses on day 3-5.
Study: NCT01649180
Drug: Axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Axitinib 5 mg orally with food every 12 hours. One cycle=28 days.
Study: NCT01291563
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 capsule of moxifloxacin (400 mg/capsule) on Day 2
Study: NCT01291563
Drug: Moxifloxacin placebo
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 capsule of moxifloxacin placebo on Day 2
Study: NCT02545972
Drug: tacrolimus extended release
Normalized name: Tacrolimus Extended Release Capsules
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: daily dosing of tacrolimus
Study: NCT03860844
Drug: Isatuximab
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: Concentrate for solution for intravenous infusion Route of administration: Intravenous
Study: NCT03860844
Drug: Dexamethasone or equivalent
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: Solution for injection or tablet Route of administration: Intravenous or oral
Study: NCT03860844
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Study: NCT03860844
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Study: NCT03860844
Drug: Liposomal daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Study: NCT03512756
Drug: SM-88 used with MPS (methoxsalen, phenytoin, sirolimus)
Normalized name: Methoxsalen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily oral therapy for cancer
Study: NCT01348880
Drug: Vardenafil ODT, (Staxyn, BAY38-9456)
DrugBank: Vardenafil (DB00862)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 10 mg of vardenafil ODT, taken without water
Study: NCT03860844
Drug: Daunorubicin (nonliposomal)
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
Study: NCT03860844
Drug: Idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Study: NCT03860844
Drug: Filgrastim or equivalent
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Study: NCT03860844
Drug: Mitoxantrone
Normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Study: NCT03860844
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Study: NCT03860844
Drug: Pegaspargase (PEG) Asparaginase
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
Study: NCT03860844
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
Study: NCT03860844
Drug: Hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection Route of administration: PO
Study: NCT03860844
Drug: L - Asparaginase (Erwinase)
Normalized name: asparaginase Injection [Erwinaze]
DrugBank: Asparaginase Escherichia coli (DB00023)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection Route of administration: Intramuscular
Study: NCT00411099
Drug: agomelatine
Normalized name: agomelatine
DrugBank: Agomelatine (DB06594)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT01948804
Drug: GnrH Antagonist/letrozole protocol (Cetrotide; serono + Femara; Novartis Pharma AG)
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01948804
Drug: GnRH antagonist protocol (Cetrotide, Serono)
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01979354
Drug: Spinal morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.15 mg spinal morphine
Study: NCT03463135
Drug: Glucopyranosyl Lipid A (GLA)
Normalized name: Glucopyranosyl Lipid A Stable Emulsion
DrugBank: G100 (DB17244)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Colloidal aqueous dispersion Route of administration: Sublingual
Study: NCT03463135
Drug: Sublingual Immuno Therapy (SLIT) Peanut Extract (PE)
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Solution Route of administration: Sublingual
Study: NCT03319706
Drug: Torrent's Olmesartan Medoxomil Tablets 40 mg
DrugBank: Olmesartan (DB00275)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02845999
Drug: fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: day -6 to day -2 : fludarabine 25 mg/m2
Study: NCT02517697
Drug: 14 Nitrogen (N) Sodium Nitrite
Normalized name: Sodium Nitrite
DrugBank: Nitrogen (DB09152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral formulation of sodium nitrite 40 mg three times daily for 12 weeks
Study: NCT02845999
Drug: interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: day -1 : addition of 1000 UI/ml of interleukin 2 to NK cells and overnight culture at 37°C, 5%CO2 ; day 0, hour +12 : 10 MUI of interleukin 2 injection, 2 times a week during 3 weeks.
Study: NCT02135510
Drug: metoclopramide
Normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02135510
Drug: dexamethason
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02135510
Drug: palonosetron
Normalized name: Palonosetron
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04487236
Drug: ZN-A-1041 Level 1 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ZN-A-1041 level 1 BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
Study: NCT04487236
Drug: ZN-A-1041 Level 2 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ZN-A-1041 level 2 BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
Study: NCT04487236
Drug: ZN-A-1041 MAD +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ZN-A-1041 MAD BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
Study: NCT04487236
Drug: ZN-A-1041+Capecitabine + Trastuzumab 8 mg/kg iv. First Cycle
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Base on 1b ZN-A-1041 dose Base on 1b Capecitabine dose Base on 1b Trastuzumab dose
Study: NCT01441934
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sildenafil 20 mg t.i.d. compared to placebo 20 mg t.i.d - 16 weeks treatment
Study: NCT01441934
Drug: Sugar pills
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo t.i.d.
Study: NCT03799536
Drug: Sotalol
Normalized name: Sotalol
DrugBank: Sotalol (DB00489)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sotalol, Tablets,160 mg, manufactured by Pharmtechnology LLC, Belarus
Study: NCT03799536
Drug: Sotalex
DrugBank: Sotalol (DB00489)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sotalex, Tablets,160 mg, manufactured by Bristol-Myers Squibb GmbH \& Co. KGaA, Germany
Study: NCT01257074
Drug: Acyclovir 50mg/g
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cream, dose 5 times daily during 5 days
Study: NCT01257074
Drug: Penciclovir 10mg/g
DrugBank: Penciclovir (DB00299)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cream, dose 5 times daily during 5 days
Study: NCT00451256
Drug: AVI-5126
Normalized name: AVI-5126
DrugBank: AVI-5126 (DB05726)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00396851
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01886352
Drug: Standard Injection of Levobupivacaine in portal sites.
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All port sites will be injected with 0.1ml/kg levobupivacaine at the end of surgery, after trocar removal.
Study: NCT01886352
Drug: Additional injection of 0,5% levobupivacaine.
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediately following insufflation 0.15ml/kg levobupivacaine will be injected in the peritoneal cavity via a trocar. At the end of the surgery, this process will be repeated with the same dose at 0.15ml/kg.
Study: NCT01886352
Drug: Intraperitoneal atomization of levobupivacaine.
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediately following insufflation the Optispray® surgical spray device will be inserted into the abdomen and directed towards the diaphragms, dome of inflated abdomen, bowel peritoneum and surgical dissection site and the study drug will be delivered as an atomized spray in the following volumes:~1. Each subdiaphragmatic area 0.05 ml/kg~2. Dome of abdomen then settling onto bowel 0.05 ml/kg~3. Surgical dissection site 0.05 ml/kg~4. At the end of the surgery - this process will be repeated with the same doses at 0.15 ml/kg.
Study: NCT00952952
Drug: Mesalamine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00414999
Drug: TG100801
DrugBank: G100 (DB17244)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04926571
Drug: Dexamethasone Oral
Normalized name: dexamethasone Oral Tablet
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: New users of Dexamethasone
Study: NCT00112632
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03206554
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Large volume local anaesthetic intraarticularly
Study: NCT01310465
Drug: sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sodium chloride, 100ml, intravenous, one time at three days postoperatively
Study: NCT00039455
Drug: alvocidib
Normalized name: Alvocidib
DrugBank: Alvocidib (DB03496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT02545751
Drug: Thymalfasin
Normalized name: Thymalfasin
DrugBank: Thymalfasin (DB04900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymalfasin treatment is given twice a week with an interval of 3-4 days until progression of other metastatic lesions. Tumor response is evaluated by assessing clinical and CT/MRI response for all the other measurable metastatic sites.
Study: NCT01946035
Drug: Doxazosin XL
DrugBank: Doxazosin (DB00590)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02986906
Drug: 5% dextrose
Normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided 5cc 5% dextrose injection between medial epicondyle and ulnar nerve
Study: NCT02986906
Drug: 2cc 0.9% normal saline+3cc Triamcinolone (30mg)
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided 2cc 0.9% normal saline+3cc Triamcinolone (30mg) injection between medial epicondyle and ulnar nerve
Study: NCT02222610
Drug: 0.5 mg ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02421640
Drug: Cisplatin+TIL
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cisplatin 100mg/m2(every three weeks),D1,D22,D43 of radiotherapy,then TIL infusing following concurrent chemoradiotherapy
Study: NCT03710122
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Firvanq by Azurity Pharmaceuticals, Inc.
Study: NCT02908126
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin drug
Study: NCT02421640
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cisplatin 100mg/m2(every three weeks),D1,D22,D43 of radiotherapy only
Study: NCT03253185
Drug: SC-007
Normalized name: camphor 0.007 MG/MG
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous
Study: NCT02126878
Drug: Kenalog
Normalized name: Kenalog
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00938678
Drug: Pegfilgrastim Hospira
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects in both treatment groups will have safety assessments and will be followed for all adverse and serious adverse events.
Study: NCT00938678
Drug: Neulasta (Amgen)
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects in both treatment groups will have safety assessments and will be followed for all adverse and serious adverse events.
Study: NCT01218581
Drug: received oral letrozole (2.5 mg/day)and goserelin subcutaneosly (3.6 mg/month)
Normalized name: goserelin 3.6 MG
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00649506
Drug: Nitrofurantoin Macrocrystals 100 mg Capsules
Normalized name: nitrofurantoin
DrugBank: Nitrofurantoin (DB00698)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg, single dose fed
Study: NCT03777059
Drug: Atogepant
Normalized name: Atogepant
DrugBank: Atogepant (DB16098)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atogepant tablet
Study: NCT01517815
Drug: Doripenem or Piperacillin/Tazobactam
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This arm is composed of 26 no overweight patients, Antibiotic (Doripenem or Piperacillin/Tazobactam) is chosen by the intensivist in charge of the case:~* in 13 no overweight patients, Pipéracilline/tazobactam will be administered in 4g IV (1h) and then 16g/24h IV continuously. Piperacillin/Tazobactam plasma dosage: after the first dose and then every 12h.~* in 13 patients no overweight: doripénème will be administered in 1g/8h with a 4h IV infusion. Doripenem plasma dosage: after the first dose and then twice a day, at peak and residual value.
Study: NCT01517815
Drug: Doripenem or Piperacillin/Tazobactam
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This arm is composed of 26 overweight patients, Antibiotic (Doripenem or Piperacillin/Tazobactam) is chosen by the intensivist in charge of the case:~* in 13 overweight patients, Pipéracilline/tazobactam will be administered in 4g IV (1h) and then 16g/24h IV continuously. Piperacillin/Tazobactam plasma dosage: after the first dose and then every 12h.~* in 13 patients overweight: doripénème will be administered in 1g/8h with a 4h IV infusion. Doripenem plasma dosage: after the first dose and then twice a day, at peak and residual value.
Study: NCT04308330
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is a phase I study of the combination of four drugs: vorinostat, vincristine, irinotecan, and temozolomide. This is called a Phase I study because the goal is to find the highest dose of vorinostat that investigators can give safely when it is used together with the chemotherapy drugs vincristine, irinotecan and temozolomide. Investigators are using vorinostat because it seems to work against cancer in test tubes and animals. It may be most effective when it is given with chemotherapy. The combination of these three agents together has never been given to children. Vincristine, irinotecan, and temozolomide are approved and used for the treatment of other types of cancer in adults and children. Vorinostat is approved and used to treat cancer in adults. The combination of these four drugs together is experimental. Investigators do not know if this combination of medicines will work in people. There is a lot that investigators do not yet know about this combination of medicines.
Study: NCT01984086
Drug: Salbutamol Sulphate 200mcg UD-DPI Blister(1.6% blend)
Normalized name: fluticasone
DrugBank: Fluticasone (DB13867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol Sulphate 200mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
Study: NCT01984086
Drug: Salbutamol Sulphate 250mcg UD-DPI Blister(1.6% blend)
Normalized name: fluticasone
DrugBank: Fluticasone (DB13867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol Sulphate 250mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
Study: NCT01984086
Drug: Salbutamol Sulphate 200mcg UD-DPI Blister(1% blend)
Normalized name: fluticasone
DrugBank: Fluticasone (DB13867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol Sulphate 200mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
Study: NCT01984086
Drug: Salbutamol Diskus 200mcg Blister
Normalized name: fluticasone
DrugBank: Fluticasone (DB13867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol Diskus 200mcg will be supplied as blister strip contained within the Diskus device. Each blister contains a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
Study: NCT01984086
Drug: Salbutamol MDI 100mcg
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol MDI 100mcg will be supplied as formulation of salbutamol sulphate (micronized) in propellant contained within the pressurised MDI device
Study: NCT01984086
Drug: Salbutamol Sulphate 250mcg UD-DPI Blister (selected from Part A)
Normalized name: fluticasone
DrugBank: Fluticasone (DB13867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation will be determined depending on the outcome of Part A.
Study: NCT01984086
Drug: Salbutamol Diskus 200mcg Blister without activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation will be determined depending on the outcome of Part A.
Study: NCT01984086
Drug: Salbutamol Diskus 200mcg Blister with activated charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation will be determined depending on the outcome of Part A.
Study: NCT01984086
Drug: Salbutamol MDI 100mcg without activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation will be determined depending on the outcome of Part A.
Study: NCT01984086
Drug: Salbutamol MDI 100mcg with activated charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation will be determined depending on the outcome of Part A.
Study: NCT00455494
Drug: AQ-13
Normalized name: AQ-13
DrugBank: AQ-13 (DB17749)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02899000
Drug: Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical acne therapy
Study: NCT01307046
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet containing losartan potassium (100 mg), once daily
Study: NCT01307046
Drug: Placebo to losartan 100 mg
Normalized name: losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo tablet to match losartan 100 mg, once daily
Study: NCT01307046
Drug: Placebo to losartan 50 mg
Normalized name: losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo tablet to match losartan 50 mg, once daily
Study: NCT00003575
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003575
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01026012
Drug: regadenoson
Normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regadenoson dose of 400 mcg will be infused over 10-20 seconds followed by a saline flush.
Study: NCT02832544
Drug: Rivaroxaban (20 mg)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban is non-inferior to VKAs for the prevention of stroke or systemic embolism in patients with AF/flutter and RVHD and potentially superior to VKAs.